Abeona Therapeutics Inc (NASDAQ:ABEO) SVP Brendan M. O’malley Purchases 8,600 Shares

Abeona Therapeutics Inc (NASDAQ:ABEO) SVP Brendan M. O’malley purchased 8,600 shares of the company’s stock in a transaction that occurred on Thursday, April 25th. The stock was acquired at an average cost of $3.24 per share, with a total value of $27,864.00. Following the transaction, the senior vice president now directly owns 188,718 shares of the company’s stock, valued at $611,446.32. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Abeona Therapeutics Trading Up 2.2 %

NASDAQ ABEO opened at $3.26 on Friday. The firm has a market cap of $89.16 million, a price-to-earnings ratio of -1.26 and a beta of 1.49. The company has a 50 day moving average of $7.23 and a 200-day moving average of $5.60. Abeona Therapeutics Inc has a 1-year low of $2.83 and a 1-year high of $9.01.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Monday, March 18th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.13). On average, analysts forecast that Abeona Therapeutics Inc will post -2.05 earnings per share for the current year.

Institutional Trading of Abeona Therapeutics

Hedge funds have recently modified their holdings of the company. Simplex Trading LLC increased its holdings in shares of Abeona Therapeutics by 1,889.9% during the third quarter. Simplex Trading LLC now owns 14,128 shares of the biopharmaceutical company’s stock worth $59,000 after buying an additional 13,418 shares in the last quarter. Jump Financial LLC bought a new stake in shares of Abeona Therapeutics during the fourth quarter valued at approximately $199,000. Schonfeld Strategic Advisors LLC bought a new stake in shares of Abeona Therapeutics during the third quarter valued at approximately $648,000. Worth Venture Partners LLC grew its stake in shares of Abeona Therapeutics by 76.6% during the third quarter. Worth Venture Partners LLC now owns 281,280 shares of the biopharmaceutical company’s stock valued at $1,184,000 after purchasing an additional 121,969 shares during the last quarter. Finally, Barclays PLC grew its stake in shares of Abeona Therapeutics by 100.0% during the third quarter. Barclays PLC now owns 371,276 shares of the biopharmaceutical company’s stock valued at $1,564,000 after purchasing an additional 185,638 shares during the last quarter. Institutional investors and hedge funds own 80.56% of the company’s stock.

Wall Street Analyst Weigh In

ABEO has been the subject of several recent research reports. StockNews.com lowered shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, April 23rd. Cantor Fitzgerald reissued an “overweight” rating and issued a $36.00 price target on shares of Abeona Therapeutics in a research report on Tuesday, April 23rd.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.